Gynecologic Cancers

Cancer Prevention Guidelines Updated

The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.

Oral Olaparib Shows Efficacy in Advanced Ovarian Cancer

A new orally active poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, has been found to have similar efficacy to pegylated liposomal doxorubicin (PLD) for the treatment of patients with ovarian cancer that has recurred or progressed following treatment with platinum-based chemotherapy.

Aflibercept Shows Clinical Activity for Malignant Ascites

Aflibercept, a potent inhibitor of vascular endothelial growth factor (VEGF), shows clinical activity and increases the time to repeat paracentesis for patients with advanced chemo-resistant ovarian cancer and recurrent symptomatic malignant ascites.